René Russo
Board Member
Xilio Therapeutics, Inc. (XLO)Equibles does not estimate personal net worth.
Get an email with a short summary when Xilio Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get XLO alertsAbout René Russo
René Russo is recorded as CEO and Board Member at Xilio Therapeutics, Inc. (XLO). The newest filing on record that lists René Russo as CEO and Board Member at Xilio Therapeutics, Inc. (XLO) is dated April 28, 2026. The proxy statement of Xilio Therapeutics, Inc. reports total compensation of $6,451,495 for René Russo in fiscal 2025, including a base salary of $643,700. Disclosed compensation is on record for 2 fiscal years. Xilio Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Xilio Therapeutics, Inc. includes Sara M. Bonstein (Chairman and Board Member), Kevin Brennan (CFO and Chief Accounting Officer), Christopher Frankenfield (COO) and 7 others.
Affiliation history
-
Current
Start not stated–present
Last confirmed April 28, 2026
-
Current
Start not stated–present
Last confirmed April 28, 2026
Company network
Leadership on record at Xilio Therapeutics, Inc.
- Sara M. Bonstein Chairman, Board Member
- Kevin Brennan CFO, Chief Accounting Officer
- Christopher Frankenfield COO
- Akintunde Bello Board Member
- Akintunde Bello, Ph.D. Board Member
- Aoife Brennan Board Member
- Aoife Brennan, M.D. Board Member
- Cheryl Blanchard Board Member
- Cheryl R. Blanchard, Ph.D. Board Member
- Daniel Curran Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Xilio Therapeutics, Inc. (XLO) | Pharm.D. President and Chief Executive Officer | $643,700 | $6,451,495 |
| 2024 | Xilio Therapeutics, Inc. (XLO) | Pharm.D. President and Chief Executive Officer | $613,947 | $1,454,729 |
Recent activity
No call appearances or filed executive changes recorded yet.